LinkOPH

BARCELONA — Micropulse laser trabeculoplasty yielded a success rate of 75% after treatment in patients with primary open angle glaucoma, according to a speaker. “The benefits of MLT [micropulse laser trabeculoplasty] are that [there are] no steroids, there is no scarring, there is no risk of infection, it is repeatable, it is a well-tolerated office procedure that can be performed under topical anesthesia, it has zero downtime, and it does not affect the success rates of future glaucoma surgeries,” Jacky W. Y. Lee, MBBS, MRCSEd, FRSCEd, FCOphthHK, FHKAM, said at (Read more...)

FALLBROOK, Calif.–(BUSINESS WIRE)–KCCO recognized with international vision award for work restoring sight to millions in developing world; VISION 2020 organization recipient of prestigious Champalimaud Vision Award.

Read more →

BARCELONA — The updated European Society of Cataract and Refractive Surgeons study on femtosecond laser-assisted cataract surgery finds that “femto does not outperform phaco,” according to Peter Barry, MD, who delivered this year’s results.Although the ESCRS FLACS study found the femtosecond procedure to result in significantly better outcomes in terms of postoperative and surgically induced astigmatism, postoperative complications outnumbered those of phaco surgery, leading to a significantly higher percentage of patients with worse visual acuity than before surgery, Barry said at the ESCRS meeting.

Read more →

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that the first patient has been enrolled in the company’s Phase 2 clinical trial using Ocata’s proprietary RPE cells in patients with atrophic (dry) age-related macular degeneration (AMD). The purpose of the trial is to evaluate safety and explore efficacy as compared to a parallel control group. Interim top-line results from the first cohort is expe

Read more →